Ali / Cibas The Bethesda System for Reporting Thyroid Cytopathology

Definitions, Criteria and Explanatory Notes
1. Auflage 2010
ISBN: 978-0-387-87666-5
Verlag: Springer
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 174 Seiten

This atlas is the offspring of the 'The National Cancer Institute (NCI) Thyroid Fine Needle Aspiration (FNA) State of the Science Conference,' hosted by the NCI and organized by Dr. Andrea Abati. Preparations for the conference began 18 months earlier with the designation of a steering committee and the establishment of a dedicated, p- manent web site. The meeting took place on October 22 and 23, 2007 in Bethesda, Maryland and was co-moderated by Susan J. Mandel and Edmund S. Cibas. The discussions and conclusions regarding terminology and morphologic criteria 1, 2 from the meeting were summarized in publications by Baloch et al. and form the framework for this atlas. The atlas is organized by the general categories of 'Nondiagnostic,' 'Benign,' 'Follicular Neoplasm/Suspicious for a Follicular Neoplasm', 'Suspicious for Malignancy,' and 'Malignant,' and it includes the defi- tions and morphologic criteria of these categories as set forth by Baloch et al. The majority of the conference participants also agreed on a category of 'undetermined significance,' which is incorporated in this atlas (Chap. 4). It is critical that the cytopathologist communicate thyroid FNA interpretations to the referring physician in terms that are succinct, unambiguous, and helpful clinically. We recognize that the terminology used here is a flexible framework that can be modified by individual laboratories to meet the needs of their providers and the patients they serve.

Autoren/Hrsg.

Ali, Syed Z.

Cibas, Edmund S.

Inhaltsverzeichnis

1;Preface;5
2;Contents;6
3;Contributors;8
4;Chapter 1;14
4.1;Overview of Diagnostic Terminology and Reporting;14
4.1.1;Format of the Report;14
5;Chapter 2;17
5.1;Nondiagnostic/Unsatisfactory;17
5.1.1;Background;17
5.1.2;Definition;18
5.1.3;Criteria for Adequacy;18
5.1.3.1;Nondiagnostic/Unsatisfactory (Figs. .2.1.–.2.7.);18
5.1.4;Explanatory Notes;22
5.1.5;Management;24
5.1.6;Sample Reports;25
5.1.6.1;Example 1 (solid nodule):;25
5.1.6.2;Example 2 (cystic lesion):;25
5.1.6.3;Example 3;25
5.2;References;25
6;Chapter 3;27
6.1;Benign;27
6.1.1;Benign Follicular Nodule;27
6.1.1.1;Background;27
6.1.1.1.1;Definition;28
6.1.1.1.2;Criteria (Figs. .3.1.–.3.13.);28
6.1.1.1.3;Explanatory Notes;33
6.1.2;Graves’ Disease (Figs. .3.15.–.3.18.);36
6.1.3;Lymphocytic (Hashimoto´s) Thyroiditis (Figs. .3.19.–.3.22.);39
6.1.3.1;Background;39
6.1.3.2;Definition;39
6.1.3.3;Criteria;39
6.1.4;Granulomatous (subacute, de Quervain´s) Thyroiditis (Fig. .3.23.);42
6.1.4.1;Criteria;42
6.1.5;Acute Thyroiditis (Fig. .3.24.);43
6.1.5.1;Criteria;43
6.1.6;Riedel´s Thyroiditis/Disease (Fig. .3.25.);43
6.1.6.1;Criteria;44
6.1.6.2;Explanatory Notes;44
6.1.6.3;Management;45
6.1.6.4;Sample Reports;46
6.2;References;47
7;Chapter 4;49
7.1;Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance;49
7.1.1;Background;49
7.1.2;Definition;49
7.1.3;Criteria (Figs 4.1–4.8);50
7.1.4;Explanatory Notes;51
7.1.5;Management;58
7.1.6;Sample Reports;58
7.2;References;60
8;Chapter 5;62
8.1;Follicular Neoplasm/Suspicious for a Follicular Neoplasm;62
8.1.1;Background;62
8.1.2;Definition;63
8.1.3;Criteria;63
8.1.4;Explanatory Notes;65
8.1.5;Management;68
8.1.6;Sample Reports;68
8.2;References;68
9;Chapter 6;70
9.1;Follicular Neoplasm, Hürthle Cell Type/Suspicious for a Follicular Neoplasm, Hürthle Cell Type;70
9.1.1;Background;70
9.1.2;Definition;71
9.1.3;Criteria;71
9.1.4;Explanatory Notes;75
9.1.5;Sample Reports;82
9.1.5.1;Example 1:;82
9.1.5.2;Example 2:;82
9.1.5.3;Example 3:;82
9.1.5.4;Example 4:;82
9.1.5.5;Example 5:;82
9.1.5.6;Example 6:;82
9.2;References;83
10;Chapter 7;85
10.1;Suspicious for Malignancy;85
10.1.1;Background;85
10.1.2;Definition;86
10.1.3;Criteria;86
10.1.3.1;Suspicious for Papillary Carcinoma;86
10.1.3.1.1;Pattern A (“Patchy Nuclear Changes Pattern,” Figs. .7.1. and .7.2.);86
10.1.3.1.2;Pattern B (“Incomplete Nuclear Changes Pattern,” Fig. .7.3.);86
10.1.3.1.3;Pattern C (“Sparsely Cellular Specimen Pattern”);88
10.1.3.1.4;Pattern D (“Cystic Degeneration Pattern,” Fig. .7.4.);88
10.1.3.2;Suspicious for Medullary Carcinoma (Figs. .7.5. and .7.6.);88
10.1.3.3;Suspicious for Lymphoma (Fig. .7.7.);90
10.1.3.4;Suspicious for Malignancy, Not Otherwise Specified;90
10.1.4;Explanatory Notes;90
10.1.4.1;Suspicious for Papillary Carcinoma;90
10.1.4.2;Suspicious for Medullary Carcinoma;95
10.1.4.3;Suspicious for Lymphoma;95
10.1.4.4;Suspicious for Malignancy, Not Otherwise Specified;96
10.1.5;Management;96
10.1.6;Sample Reports;97
10.1.6.1;Example 1:;97
10.1.6.2;Example 2:;97
10.2;References;97
11;Chapter 8;100
11.1;Papillary Thyroid Carcinoma and Variants;100
11.1.1;Background;100
11.1.2;Papillary Thyroid Carcinoma (Figs. 8.1–8.13);101
11.1.2.1;Definition;101
11.1.2.2;Criteria (for All Types of PTC, Conventional and Variants);101
11.1.2.3;Explanatory Notes;103
11.1.3;Variants of Papillary Thyroid Carcinoma;109
11.1.3.1;Follicular Variant (Figs. 8.14–8.16);110
11.1.3.1.1;Definition;110
11.1.3.1.2;Background;111
11.1.3.1.3;Criteria;111
11.1.3.1.4;Explanatory Notes;112
11.1.3.2;Macrofollicular Variant (Figs. 8.17, 8.18);112
11.1.3.2.1;Definition;112
11.1.3.2.2;Criteria;112
11.1.3.2.3;Explanatory Notes;113
11.1.3.3;Cystic Variant (Figs. 8.19, 8.20);113
11.1.3.3.1;Definition;113
11.1.3.3.2;Criteria;114
11.1.3.3.3;Explanatory Notes;115
11.1.3.4;Oncocytic Variant (Figs. 8.21, 8.22);115
11.1.3.4.1;Definition;115
11.1.3.4.2;Criteria;116
11.1.3.4.3;Explanatory Notes;117
11.1.3.5;Warthin-like Variant;117
11.1.3.5.1;Definition;117
11.1.3.5.2;Criteria;117
11.1.3.5.3;Explanatory Notes;117
11.1.3.6;Tall Cell Variant (Figs. 8.23, 8.24);118
11.1.3.6.1;Definition;118
11.1.3.6.2;Criteria;118
11.1.3.6.3;Explanatory Notes;119
11.1.3.7;Columnar Cell Variant (Figs. 8.25, 8.26);120
11.1.3.7.1;Definition;120
11.1.3.7.2;Criteria;120
11.1.3.7.3;Explanatory Notes;120
11.1.3.8;Hyalinizing Trabecular Tumor (Fig. 8.27);121
11.1.3.8.1;Definition;121
11.1.3.8.2;Criteria;121
11.1.3.8.3;Explanatory Notes;122
11.1.3.9;Other Rare Variants;122
11.1.3.9.1;Management;122
11.1.4;Sample Reports;123
11.1.4.1;Example 1;123
11.1.4.2;Example 2;123
11.2;References;123
12;Chapter 9;126
12.1;Medullary Thyroid Carcinoma;126
12.1.1;Background;126
12.1.2;Definition;127
12.1.3;Criteria (Figs. 9.1–9.16);127
12.1.4;Explanatory Notes;134
12.1.5;Management;135
12.1.6;Sample Reports;135
12.2;References;136
13;Chapter 10;138
13.1;Poorly Differentiated Thyroid Carcinoma;138
13.1.1;Background;138
13.1.2;Definition;138
13.1.3;Criteria (Figs. .10.1–10.12);139
13.1.4;Explanatory Notes;139
13.1.5;Management;146
13.1.6;Sample Reports;146
13.2;References;147
14;Chapter 11;148
14.1;Undifferentiated (Anaplastic) Carcinoma and Squamous Cell Carcinoma of the Thyroid;148
14.1.1;Undifferentiated (Anaplastic) Thyroid Carcinoma;148
14.1.1.1;Background;148
14.1.1.2;Definition;149
14.1.1.3;Criteria (Figs. .11.1.–.11.15.);149
14.1.1.4;Explanatory Notes;151
14.1.1.5;Management;158
14.1.2;Squamous Cell Carcinoma of the Thyroid;158
14.1.2.1;Definition;158
14.1.2.2;Criteria (Fig. .11.16.);158
14.1.2.3;Explanatory Notes and Management;158
14.1.2.4;Sample Reports;159
14.2;References;160
15;Chapter 12;161
15.1;Metastatic Tumors and Lymphomas;161
15.1.1;Background;161
15.1.2;Metastatic Renal Cell Carcinoma;162
15.1.2.1;Definition;162
15.1.2.2;Criteria (Figs. .12.1. and .12.2.);162
15.1.2.3;Explanatory Notes;162
15.1.3;Metastatic Malignant Melanoma;163
15.1.3.1;Definition;163
15.1.3.2;Criteria (Figs. .12.3. and .12.4.);164
15.1.3.3;Explanatory Notes;164
15.1.4;Metastatic Adenocarcinoma from the Breast;165
15.1.4.1;Definition;165
15.1.4.2;Criteria (Fig. .12.5.);165
15.1.4.3;Explanatory Notes;166
15.1.5;Metastatic Pulmonary Carcinoma;167
15.1.6;Other Metastatic Malignancies;168
15.1.7;Lymphoma Involving the Thyroid Gland;169
15.1.7.1;Definition;169
15.1.7.2;Criteria;170
15.1.7.3;Explanatory Notes;170
15.1.7.4;Extranodal Marginal Zone B-Cell Lymphoma (MALT Lymphoma);171
15.1.7.5;Diffuse Large B-Cell Lymphoma;171
15.1.8;Sample Reports;172
15.1.8.1;Example 1:;173
15.1.8.2;Example 2:;173
15.2;References;173
16;Index;175